Physician profile
Sanjay Chabra
NPI 1316916125
$3,291,946.47
in general payments reported to CMS, 2019-2025
44 companies · $412K in 2025
The $412K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586K · 2020: $299K · 2021: $433K · 2022: $576K · 2023: $486K · 2024: $500K · 2025: $412K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $917K · Travel and Lodging: $201K · Consulting Fee: $127K · Honoraria: $117K · Food and Beverage: $36K · Education: $67.34 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $916,794.25 |
| Travel and Lodging | $201,029.60 |
| Consulting Fee | $127,177.25 |
| Honoraria | $117,021.25 |
| Food and Beverage | $35,767.06 |
| Education | $67.34 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $682,813.87 | 2019-2023 | Krystexxa |
| Abbvie INC. | $538,762.19 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $427,552.42 | 2019-2025 | Krystexxa, Tavneos, Otezla |
| Astrazeneca Pharmaceuticals Lp | $253,256.68 | 2021-2025 | Saphnelo, Tezspire |
| Lilly USA, LLC | $227,209.97 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Glaxosmithkline, LLC. | $198,022.98 | 2019-2025 | Benlysta, Nucala |
| Ucb, INC. | $185,585.97 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $167,378.54 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $138,047.55 | 2021-2025 | Lupkynis |
| Celgene Corporation | $116,415.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $85,882.45 | 2019-2025 | Cosentyx |
| Mallinckrodt Hospital Products INC. | $83,279.33 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $73,112.97 | 2022-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $64,218.60 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $23,959.54 | 2019 |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Chabra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.